Brady Kelly
Known title: See RemarksCIK: 0002117686
Associated companies
Transaction History
| MCRB | ▼ Sell | Open Market | 64 | $291 | 8/17/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 181 | — | 8/15/2026 | View on chart |
| MCRB | ▼ Sell | Open Market | 59 | $444 | 5/18/2026 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 180 | — | 5/15/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026
Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.